Business

Valeant may be on the verge of a technical default as its lender demand not one but two pounds of flesh, it may be suffering imploding sales, it may have fired the entire salesforce for the female libido drug Addyi (which it acquired late last year), and it may be trying to pin all of its allegedly criminal book-cooking on its former CFO (who used to be a fromer head Goldman banker), the same CFO who refuses to resign from Valeant's board even though Valeant clearly wants him gone, but at least minutes ago, an ad hoc committee from Valeant's board (yes the same board where the former scapeg

There were two notable things about a report released by the ECB this morning as part of its Occasional Paper Series titled "Profit distribution and loss coverage rules for central banks", which purportedly analyzes "how profit distribution rules can affect the amounts distributed and the financial strength of central banks."

Days before the ICIJ released this weekend's trove of "Panama Papers" international tax haven data involving Panamaian law firm Mossack Fonseca, Bloomberg conducted an interview on March 29 with the two founding lawyers. In it, it found that even before the full leak was about to be made semi-public (any of the at least 441 US clients are still to be disclosed), the Panama law firm knew that the game was already largely over.

With the USDJPY crashing to a fresh 17 month low, sending the Nikkei down 2.3% and taking out levels during which we have seen direct BOJ intervention in both February and March, many were wondering how a panicking Japan would try to push its currency lower. The answer was revealed moments ago, with the following Reuters headlines:

• Panama Papers: Biggest Banks Are Top Users of Offshore Services (WSJ)
• Panama Papers probes opened, China limits access to news on leaks (Reuters)
• Credit Suisse CEO Distances Bank From ‘Panama Papers’ (WSJ)
• Fed's Evans says market more pessimistic on U.S. rate hikes (Reuters)
• IMF's Lagarde Says Risks to Weak Global Recovery Are Increasing (BBG)
• New U.S. inversion rules threaten Pfizer-Allergan deal (Reuters)
• Time Is Running Out (Again) for Greece (BBG)